Presentation is loading. Please wait.

Presentation is loading. Please wait.

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya.

Published byMaria do Loreto de Abreu Conceição Modified over 6 years ago

Similar presentations

Presentation on theme: "A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya."— Presentation transcript:

1 A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya Amano, MD, PhD, Wei-Che Ko, MS, Jillian M. Richmond, PhD, Michelle Kelley, MSN, RN, Maryanne Makredes Senna, MD, Andrea Pearson, MD, Sandhya Chowdary, MD, Celia Hartigan, RN, MPH, Bruce Barton, PhD, John E. Harris, MD, PhD  Journal of the American Academy of Dermatology  Volume 76, Issue 1, Pages e3 (January 2017) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Relative change in Vitiligo Area Scoring Index (VASI) score between visits 1 and 4 in placebo (A) and simvastatin (B) groups. Thick purple line represents the mean change of each group. Visit 1, 0 months; Visit 2, 1 month; Visit 3, 3 months; Visit 4, 6 months. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Supplemental Fig 1 Vitiligo Area Scoring Index (VASI) score formula.
Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Supplemental Fig 2 Comparison of serum CXCL10 levels between treatment and placebo groups. Participant 8 (simvastatin [simv] group) was not included because he withdrew before a second CXCL10 level was obtained. Other withdrawn participants were included, using the CXCL10 from their final visits. NS, Not significant. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.
Clavi syphilitici–an unusual presentation of syphilis

Clavi syphilitici–an unusual presentation of syphilis
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
A girl with a solitary red bulla

A girl with a solitary red bulla
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Similar presentations

Ads by Google